Hodgkin's Disease
Conditions
Keywords
Pulmonary function, Bleomycin-based chemotherapy, mediastinal irradiation
Brief summary
The purpose of this study is to find out the impact Bleomycin-containing chemotherapy, given with or without chest radiation therapy, on patients' lung function over time.
Detailed description
* The tests and procedures in this study are part of regular cancer care but this study offers more structured timing of these standard tests. * Due to the potential lung toxicity associated with bleomycin-based chemotherapy, pulmonary function tests are routinely performed. Pulmonary function tests will be performed by a licensed, registered respiratory therapist and performed prior to the beginning of treatment, between the chemotherapy and radiation therapy (only for patients receiving both chemotherapy and radiation therapy), and at approximately 1 month, 6 months, 1 year and 2 years after the completion of all treatments. * A CAT scan will be performed prior to the beginning of treatment, and approximately 1 month, 6 months, 1 year and 2 years after the completion of all treatments. * A self-administered questionnaire will be performed on the days the patient is undergoing pulmonary function tests.
Interventions
PROCEDUREPulmonary Function Tests
Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
PROCEDURECAT Scan
Obtained at different time points during the study depending upon standard of care chemotherapy treatment
Sponsors
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with newly diagnosed classical Hodgkin's disease, with mediastinal involvement * Bleomycin-based chemotherapy alone or in combination with mediastinal irradiation
Exclusion criteria
* Prior chest irradiation * Mediastinal irradiation received at an outside institution * Refractory or progressive disease on treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary function | 2 years | Changes in pulmonary function over time |
Countries
United States
Outcome results
None listed